⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LTRN News
Lantern Pharma Inc. Common Stock
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
accessnewswire.com
SHAZ
LTRN
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
AVBP
SMMT
MRUS
MRK
GNPX
CGEM
ABBV
BMY
BDTX
LTRN
PFE
JNJ
LLY
Lantern Pharma to Present at the 7 th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
businesswire.com
LTRN
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
businesswire.com
LTRN
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
accessnewswire.com
SNYR
DVLT
NTHI
LTRN
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
businesswire.com
LTRN
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
accessnewswire.com
LTRN
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
accessnewswire.com
LTRN
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
businesswire.com
LTRN
Lantern Pharma Presents LP-284 Clinical Data at 25 th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
businesswire.com
LTRN
LTRN